ResMed set to raise up to $172.5 million
This article was originally published in Clinica
ResMed, which makes and sells equipment for the diagnosis and treatment of sleep-disordered breathing, plans to raise $150 million through a private placement of its convertible subordinated notes, due 2006. The New York company says it may increase its sale by $22.5 million if there is sufficient demand. It plans to use part of the proceeds to pay down debt taken on to buy MAP Medizin-Technologie in February.
You may also be interested in...
EU Regulatory Round-Up, February 2020: Brexit And Swixit Threaten Huge Disruption Amidst MDR Uncertainty
Complying with the EU’s new Medical Device Regulation would be hard enough. But more layers of uncertainty – especially Brexit and Swixit ̶ mean European medtech is navigating very turbulent waters right now.
Fresenius Kabi has reported sales ahead by 6% in 2019, as growth in emerging markets helped to offset a subdued increase in North America. Meanwhile, the firm has pushed back financial expectations for its biosimilars by a year.
Fresenius Kabi and Vifor Pharma have agreed to create a joint venture in China for intravenous iron products.